FDA Should Have Larger Role In Trade Talks, Hamburg Says
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA commissioner believes the agency needs to have “a full place at the table,” rather than being summoned into the process late and viewed as obstructionist when it raises public health concerns.
You may also be interested in...
U.S. FDA Wary About “Paying The Price” For Mistakes Based On Foreign Data
It is going to take time for the public and policymakers to get comfortable with the idea of U.S. FDA making regulatory decisions based on information from other countries, Commissioner Hamburg says.
Foreign Regulatory Systems Can Be Strengthened By Receiving FDA Inspection Data, IOM Says
Institute of Medicine report recommends how FDA, industry and other stakeholders can strengthen food and drug regulatory systems abroad. It calls for FDA to provide incentives for foreign regulators to meet U.S. standards and facilitate training and for the government to help hold importers liable.
Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing
Commissioner Robert Califf discussed the agency’s request for $12.3m to address shortages and legislation to require that manufacturers provide more detailed information about increased demand and supply chain vulnerabilities.